---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-25-000006"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:52:10.599607+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics reports Q4 2024 net loss of $20.4M; cash runway through Q2 2026

## Summary
- Cash and cash equivalents $111.0M at Dec 31, 2024; sufficient to fund operations through Q2 2026.
- Net loss $20.4M in Q4 2024 vs $12.0M in Q4 2023; full year net loss $70.5M vs $37.4M.
- Collaboration revenue $0 in Q4 2024 as Jazz obligation completed; full year $1.9M vs $19.9M.
- WTX-124 monotherapy melanoma expansion arm expected fully enrolled H1 2025; combination arm by end of 2025.
- Plan to meet with FDA in H2 2025 for registrational pathways; interim data expected Q4 2025.

## SEC filing metadata
- accession: 0001785530-25-000006
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553025000006/0001785530-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553025000006/howl-20250311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-25-000006
- JSON: https://secwatch.observer/filing/0001785530-25-000006.json
- Plain text: https://secwatch.observer/filing/0001785530-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.